Myelo001
Acute Radiation Syndrome (ARS)
Key Facts
About Myelo Therapeutics
Myelo Therapeutics is a clinical-stage biotech company advancing Myelo001, a small molecule with dual applications in biodefense and oncology supportive care. The company's mission is to address the severe health consequences of radiation exposure, whether from a nuclear incident or cancer therapy, by developing treatments to mitigate bone marrow toxicity. Its programs are supported by prestigious grants from the US National Institutes of Health and the European Commission's European Defence Fund. Following its 2023 acquisition by isotope technology leader Eckert & Ziegler, Myelo operates as a strategically positioned subsidiary with enhanced resources for development.
View full company profileAbout Myelo Therapeutics
Myelo Therapeutics is a clinical-stage biotech company advancing Myelo001, a small molecule with dual applications in biodefense and oncology supportive care. The company's mission is to address the severe health consequences of radiation exposure, whether from a nuclear incident or cancer therapy, by developing treatments to mitigate bone marrow toxicity. Its programs are supported by prestigious grants from the US National Institutes of Health and the European Commission's European Defence Fund. Following its 2023 acquisition by isotope technology leader Eckert & Ziegler, Myelo operates as a strategically positioned subsidiary with enhanced resources for development.
View full company profile